FDA Clears Durvalumab-Enfortumab Combo for Muscle Invasive Bladder Cancer
PFE sits 22% above its 52-week low of $23.62.
Summary
The FDA approved durvalumab in combination with enfortumab vedotin-ejfv for muscle invasive bladder cancer, adding a label expansion in a setting where treatment options are limited. This is the second oncology approval for Pfizer in roughly five weeks, following the October 7 clearance of TUKYSA as maintenance therapy in HER2-positive metastatic breast cancer. The company is leaning on its oncology pipeline to offset a 40% drop in nine-month net income to $5.68 billion, driven by $4.3 billion of impairments, disclosed in the Q3 10-Q. The approval itself carries no disclosed revenue figure, so the near-term financial impact depends on how quickly the regimen is adopted in the perioperative setting.
At the time of this announcement, PFE was trading at $28.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $164.5B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.